Quest Diagnostics (DGX) to Release Quarterly Earnings on Tuesday

Quest Diagnostics (NYSE:DGX) is expected to post its quarterly earnings results before the market opens on Tuesday, April 22nd. Analysts expect Quest Diagnostics to post earnings of $2.18 per share and revenue of $2.63 billion for the quarter. Quest Diagnostics has set its FY 2025 guidance at 9.550-9.800 EPS.Individual that are interested in participating in the company’s earnings conference call can do so using this link.

Quest Diagnostics (NYSE:DGX) last announced its earnings results on Thursday, January 30th. The medical research company reported $2.23 earnings per share for the quarter, beating analysts’ consensus estimates of $2.19 by $0.04. Quest Diagnostics had a net margin of 8.80% and a return on equity of 15.07%. On average, analysts expect Quest Diagnostics to post $10 EPS for the current fiscal year and $10 EPS for the next fiscal year.

Quest Diagnostics Stock Down 0.4 %

Shares of NYSE:DGX opened at $163.75 on Monday. The firm has a fifty day moving average of $168.62 and a 200 day moving average of $160.36. Quest Diagnostics has a 52-week low of $128.38 and a 52-week high of $178.87. The company has a debt-to-equity ratio of 0.82, a quick ratio of 1.02 and a current ratio of 1.10. The firm has a market capitalization of $18.28 billion, a PE ratio of 21.29, a price-to-earnings-growth ratio of 2.16 and a beta of 0.78.

Quest Diagnostics Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, April 21st. Shareholders of record on Monday, April 7th will be paid a $0.80 dividend. The ex-dividend date is Monday, April 7th. This represents a $3.20 annualized dividend and a yield of 1.95%. This is a positive change from Quest Diagnostics’s previous quarterly dividend of $0.75. Quest Diagnostics’s dividend payout ratio is currently 41.61%.

Insiders Place Their Bets

In other Quest Diagnostics news, Director Vicky B. Gregg sold 1,250 shares of the stock in a transaction on Wednesday, February 5th. The stock was sold at an average price of $164.57, for a total transaction of $205,712.50. Following the sale, the director now directly owns 16,867 shares in the company, valued at approximately $2,775,802.19. This trade represents a 6.90 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Mark E. Delaney sold 403 shares of the business’s stock in a transaction on Wednesday, February 5th. The stock was sold at an average price of $164.30, for a total value of $66,212.90. Following the completion of the transaction, the senior vice president now owns 4,624 shares of the company’s stock, valued at $759,723.20. This represents a 8.02 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 55,903 shares of company stock valued at $9,460,221. Insiders own 8.16% of the company’s stock.

Institutional Investors Weigh In On Quest Diagnostics

An institutional investor recently bought a new position in Quest Diagnostics stock. Brighton Jones LLC purchased a new stake in shares of Quest Diagnostics Incorporated (NYSE:DGX) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 2,144 shares of the medical research company’s stock, valued at approximately $323,000. Hedge funds and other institutional investors own 88.06% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have issued reports on DGX shares. Robert W. Baird raised their price objective on Quest Diagnostics from $190.00 to $191.00 and gave the company an “outperform” rating in a research note on Thursday, March 20th. Barclays boosted their price objective on shares of Quest Diagnostics from $168.00 to $175.00 and gave the company an “equal weight” rating in a research report on Friday, January 31st. JPMorgan Chase & Co. raised their target price on shares of Quest Diagnostics from $173.00 to $180.00 and gave the stock a “neutral” rating in a research report on Tuesday, February 4th. Citigroup cut shares of Quest Diagnostics from a “buy” rating to a “neutral” rating and set a $185.00 price target on the stock. in a research report on Tuesday, March 4th. Finally, UBS Group raised their price objective on shares of Quest Diagnostics from $166.00 to $170.00 and gave the stock a “neutral” rating in a report on Monday, February 3rd. Eight research analysts have rated the stock with a hold rating, seven have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $181.33.

Quest Diagnostics Company Profile

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.